Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cti Biopharm Corp (CTIC)

Cti Biopharm Corp (CTIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 223,877
  • Shares Outstanding, K 93,282
  • Annual Sales, $ 0 K
  • Annual Income, $ -52,450 K
  • 60-Month Beta 0.70
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.43
Trade CTIC with:

Options Overview

Details
  • Implied Volatility 99.90%
  • Historical Volatility 33.02%
  • IV Percentile 13%
  • IV Rank 10.80%
  • IV High 508.78% on 09/08/20
  • IV Low 50.42% on 07/21/21
  • Put/Call Vol Ratio 0.09
  • Today's Volume 59
  • Volume Avg (30-Day) 186
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 11,677
  • Open Int (30-Day) 11,126

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.21 +8.14%
on 07/19/21
2.65 -9.81%
on 07/06/21
-0.02 (-0.83%)
since 06/28/21
3-Month
2.15 +11.16%
on 05/14/21
2.65 -9.81%
on 07/06/21
-0.13 (-5.16%)
since 04/28/21
52-Week
0.96 +148.21%
on 09/04/20
4.13 -42.13%
on 03/22/21
+0.78 (+48.45%)
since 07/28/20

Most Recent Stories

More News
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as...

CTIC : 2.39 (-0.42%)
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an...

CTIC : 2.39 (-0.42%)
Insights on the Myeloproliferative Neoplasm Drugs Global Market to 2027 - Featuring Gamida Cell, Sierra Oncology & CTI BioPharma Among Others - ResearchAndMarkets.com

The "Myeloproliferative Neoplasm Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

CTIC : 2.39 (-0.42%)
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside...

CTIC : 2.39 (-0.42%)
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards...

CTIC : 2.39 (-0.42%)
CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Wednesday, June 16

/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at . The conference will be held in a...

CTIC : 2.39 (-0.42%)
CTI BioPharma Reports First Quarter 2021 Financial Results

, /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended .

CTIC : 2.39 (-0.42%)
Thinking about buying stock in Vertex Energy, CTI BioPharma, Peabody Energy, Express, or US Well Services?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTNR, CTIC, BTU, EXPR, and USWS.

USWS : 0.9998 (+9.27%)
CTIC : 2.39 (-0.42%)
VTNR : 8.74 (+6.07%)
BTU : 10.77 (+4.97%)
EXPR : 4.81 (-4.18%)
CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis

, /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for pacritinib as a treatment for myelofibrosis...

CTIC : 2.39 (-0.42%)
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

, /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to six new employees as equity inducement awards...

CTIC : 2.39 (-0.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its...

See More

Key Turning Points

3rd Resistance Point 2.51
2nd Resistance Point 2.48
1st Resistance Point 2.44
Last Price 2.39
1st Support Level 2.37
2nd Support Level 2.34
3rd Support Level 2.30

See More

52-Week High 4.13
Fibonacci 61.8% 2.92
Fibonacci 50% 2.55
Last Price 2.39
Fibonacci 38.2% 2.17
52-Week Low 0.96

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar